Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 224

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

Open access
Barratt, Jonathan, Lafayette, Richard, Kristensen, Jens, Stone, Andrew, Cattran, Daniel, Floege, Jürgen, Tesar, Vladimir, Trimarchi, Hernán, Zhang, Hong, Eren, Necmi, Paliege, Alexander, Rovin, Brad H., Fragale, Guillermo, Karl, Alejandra, Losisolo, Patricia, Trimarchi, Hernán, Hoyos, Ivan Gonzalez, Lampo, Mauro Guillermo, Monkowski, Matias, De La Fuente, Jorge, Alvarez, Magdalena, Stoppa, Daniela, Chiurchiu, Carlos, Novoa, Pablo Antonio, Orias, Marcelo, Barron, Maria Belen, Giotto, Ana, Arriola, Mariano, Cassini, Evelin, Maldonado, Rafael, Dionisi, Maria Paula, Ryan, Jessica, Toussaint, Nigel, Luxton, Grant, Peh, Chen Au, Levidiotis, Vicki, Francis, Ross, Phoon, Richard, Fedosiuk, Elena, Toropilov, Dmitry, Yakubtsevich, Ruslan, Mikhailova, Elena, Bovy, Christophe, Demoulin, Nathalie, Hougardy, Jean-Michel, Maes, Bart, Speeckaert, Marijn, Laurin, Louis-Philippe, Barbour, Sean, Masse, Melanie, Hladunewich, Michelle, Reich, Heather, Cournoyer, Serge, Tennankore, Karthik, Barbour, Sean, Lv, Jicheng, Liu, Zhangsuo, Wang, Caili, Li, Shaomei, Luo, Qun, Ni, Zhaohui, Yan, Tiekun, Fu, Ping, Cheng, Hong, Liu, Bicheng, Lu, Wanhong, Wang, Jianqin, Chen, Qinkai, Wang, DeGuang, Xiong, Zuying, Chen, Menghua, Xu, Yan, Wei, Jiali, Pai, Pearl, Chen, Lianhua, Rehorova, Jitka, Maixnerova, Dita, Safranek, Roman, Rychlik, Ivan, Hruby, Miroslav, Makela, Satu, Vaaraniemi, Kati, Ortiz, Fernanda, Alamartine, Eric, Daroux, Maite, Cartery, Claire, Vrtovsnik, Francois, Serre, Jean-Emmanuel, Stamellou, Eleni, Vielhauer, Volker, Hugo, Christian, Budde, Klemens, Otte, Britta, Nitschke, Martin, Ntounousi, Evangelia, Boletis, Ioannis, Papagianni, Aikaterini, Goumenos, Dimitrios, Stylianou, Konstantinos, Zermpala, Synodi, Esposito, Ciro, Cozzolino, Mario Gennaro, Viganò, Sara Maria, Gesualdo, Loreto, Nowicki, Michal, Stompor, Tomasz, Kurnatowska, Ilona, Kim, Sung Gyun, Kim, Yong-Lim, Na, Ki-Ryang, Kim, Dong Ki, Kim, Su-Hyun, Porras, Luis Quintana, Garcia, Eva Rodriguez, Pamplona, Irene Agraz, Segarra, Alfons, Goicoechea, Marian, Fellstrom, Bengt, Lundberg, Sigrid, Hemmingsson, Peter, Guron, Gregor, Sandell, Anna, Chen, Cheng-Hsu, Tokgoz, Bulent, Duman, Soner, Altiparmak, Mehmet Riza, Ergul, Metin, Maxwell, Peter, Mark, Patrick, McCafferty, Kieran, Khwaja, Arif, Cheung, Chee Kay, Hall, Matthew, Power, Albert, Kanigicherla, Durga, Baker, Richard, Moriarty, Jim, Mohamed, Amr, Aiello, Joseph, Canetta, Pietro, Ayoub, Isabelle, Robinson, Derrick, Thakar, Surabhi, Mottl, Amy, Sachmechi, Isaac, Fischbach, Bernard, Singh, Harmeet, Mulhern, Jeffrey, Kamal, Fahmeedah, Linfert, Douglas, Rizk, Dana, Wadhwani, Shikha, Sarav, Menaka, Campbell, Kirk, Coppock, Gaia, Luciano, Randy, Sedor, John, Avasare, Rupali, Lau, Wai Lang · 2023 · Kidney International

Abstract

The therapeutic potential of a novel, targeted-release formulation of oral budesonide (Nefecon) for the treatment of IgA nephropathy (IgAN) was first demonstrated by the phase 2b NEFIGAN trial. To verify these findings, the phase 3 NefigArd trial tested the efficacy and safety of nine months of treatment with Nefecon (16 mg/d) versus placebo in adult patients with primary IgAN at risk of progressing to kidney failure (ClinicalTrials.gov: NCT03643965). NefIgArd was a multicenter, randomized, double-blind, placebo-controlled two-part trial. In Part A, 199 patients with IgAN were treated with Nefecon or placebo for nine months and observed for an additional three months. The primary endpoint for Part A was 24-hour urine protein-to-creatinine ratio (UPCR) after nine months. Secondary efficacy outcomes evaluated included estimated glomerular filtration rate (eGFR) at nine and 12 months and the UPCR at 12 months. At nine months, UPCR was 27% lower in the Nefecon group compared with placebo, along with a benefit in eGFR preservation corresponding to a 3.87 ml/min/1.73 m 2 difference versus placebo (both significant). Nefecon was well-tolerated, and treatment-emergent adverse events were mostly mild to moderate in severity and reversible. Part B is ongoing and will be reported on later. Thus, NefIgArd is the first phase 3 IgA nephropathy trial to show clinically important improvements in UPCR and eGFR and confirms the findings from the phase 2b NEFIGAN study.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.kint.2022.09.017

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 224

Metadata

Authors
Barratt, J., Lafayette, R., Kristensen, J., Stone, A., Cattran, D., Floege, J., Tesar, V., Trimarchi, H., Zhang, H., Eren, N., Paliege, A., Rovin, B. H., Fragale, G., Karl, A., Losisolo, P., Trimarchi, H., Hoyos, I. G., Lampo, M. G., Monkowski, M., De La Fuente, J., Alvarez, M., Stoppa, D., Chiurchiu, C., Novoa, P. A., Orias, M., Barron, M. B., Giotto, A., Arriola, M., Cassini, E., Maldonado, R., Dionisi, M. P., Ryan, J., Toussaint, N., Luxton, G., Peh, C. A., Levidiotis, V., Francis, R., Phoon, R., Fedosiuk, E., Toropilov, D., Yakubtsevich, R., Mikhailova, E., Bovy, C., Demoulin, N., Hougardy, J.-M., Maes, B., Speeckaert, M., Laurin, L.-P., Barbour, S., Masse, M., Hladunewich, M., Reich, H., Cournoyer, S., Tennankore, K., Barbour, S., Lv, J., Liu, Z., Wang, C., Li, S., Luo, Q., Ni, Z., Yan, T., Fu, P., Cheng, H., Liu, B., Lu, W., Wang, J., Chen, Q., Wang, D., Xiong, Z., Chen, M., Xu, Y., Wei, J., Pai, P., Chen, L., Rehorova, J., Maixnerova, D., Safranek, R., Rychlik, I., Hruby, M., Makela, S., Vaaraniemi, K., Ortiz, F., Alamartine, E., Daroux, M., Cartery, C., Vrtovsnik, F., Serre, J.-E., Stamellou, E., Vielhauer, V., Hugo, C., Budde, K., Otte, B., Nitschke, M., Ntounousi, E., Boletis, I., Papagianni, A., Goumenos, D., Stylianou, K., Zermpala, S., Esposito, C., Cozzolino, M. G., Viganò, S. M., Gesualdo, L., Nowicki, M., Stompor, T., Kurnatowska, I., Kim, S. G., Kim, Y.-L., Na, K.-R., Kim, D. K., Kim, S.-H., Porras, L. Q., Garcia, E. R., Pamplona, I. A., Segarra, A., Goicoechea, M., Fellstrom, B., Lundberg, S., Hemmingsson, P., Guron, G., Sandell, A., Chen, C.-H., Tokgoz, B., Duman, S., Altiparmak, M. R., Ergul, M., Maxwell, P., Mark, P., McCafferty, K., Khwaja, A., Cheung, C. K., Hall, M., Power, A., Kanigicherla, D., Baker, R., Moriarty, J., Mohamed, A., Aiello, J., Canetta, P., Ayoub, I., Robinson, D., Thakar, S., Mottl, A., Sachmechi, I., Fischbach, B., Singh, H., Mulhern, J., Kamal, F., Linfert, D., Rizk, D., Wadhwani, S., Sarav, M., Campbell, K., Coppock, G., Luciano, R., Sedor, J., Avasare, R., & Lau, W. L.
Venue
Kidney International
Publisher
Elsevier BV
Published
2023-02
Volume
103
Issue
2
Pages
391-402
ISSN
0085-2538 (ISSN-L)
OpenAlex
W4306757577
Cited by
224
References
5
FWCI
25.29
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. https://app.cochat.ai/papers/10.1016/j.kint.2022.09.017
The paper
Barratt, J., Lafayette, R., Kristensen, J., Stone, A., Cattran, D., Floege, J., Tesar, V., Trimarchi, H., Zhang, H., Eren, N., Paliege, A., Rovin, B. H., Fragale, G., Karl, A., Losisolo, P., Trimarchi, H., Hoyos, I. G., Lampo, M. G., Monkowski, M., . . . Lau, W. L. (2023). Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney International. https://doi.org/10.1016/j.kint.2022.09.017

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.